(-0.03%) 5 204.75 points
(0.02%) 39 004 points
(-0.12%) 18 173 points
(-0.18%) $78.34
(-1.46%) $2.16
(-0.08%) $2 329.40
(-0.62%) $27.44
(0.05%) $965.40
(0.07%) $0.929
(0.28%) $10.85
(0.19%) $0.797
(-0.46%) $90.93
22.56% $ 1.630
@ $0.657
Wydano: 14 vas. 2024 @ 22:30
Zwrot: 148.29%
Poprzedni sygnał: vas. 14 - 16:30
Poprzedni sygnał:
Zwrot: 6.16 %
Live Chart Being Loaded With Signals
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...
Stats | |
---|---|
Dzisiejszy wolumen | 13.31M |
Średni wolumen | 10.02M |
Kapitalizacja rynkowa | 419.44M |
EPS | $-0.0300 ( 2024-05-03 ) |
Następna data zysków | ( $-0.0600 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.27 |
ATR14 | $0.00800 (0.49%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Qamar Huma | Buy | 308 465 | Option (Right to Buy) |
2024-03-18 | Qamar Huma | Sell | 0 | Common Stock |
2023-09-15 | Breininger Michael | Buy | 0 | |
2024-01-03 | Musunuri Shankar | Sell | 180 204 | Common Stock |
2024-01-03 | Upadhyay Arun | Sell | 41 633 | Common Stock |
INSIDER POWER |
---|
65.41 |
Last 96 transactions |
Buy: 10 862 012 | Sell: 2 992 475 |
Wolumen Korelacja
Ocugen Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
EQRR | 0.944 |
PVAL | 0.943 |
RNA | 0.942 |
THRN | 0.938 |
RAIL | 0.936 |
DVLU | 0.935 |
PCAR | 0.934 |
SG | 0.934 |
SHLD | 0.933 |
LFMDP | 0.932 |
10 Najbardziej negatywne korelacje | |
---|---|
RMRM | -0.938 |
RGC | -0.934 |
UONEK | -0.926 |
TCPC | -0.922 |
VORB | -0.921 |
TSP | -0.919 |
BRQS | -0.918 |
HCDIP | -0.916 |
AGRX | -0.91 |
QNRX | -0.909 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ocugen Inc Korelacja - Waluta/Towar
Ocugen Inc Finanse
Annual | 2023 |
Przychody: | $6.04M |
Zysk brutto: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2023 |
Przychody: | $6.04M |
Zysk brutto: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-1.07M (0.00 %) |
EPS: | $-0.360 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej